CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 252 enrolled
Drug / intervention
sevoflurane +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05822817
NCT05822817Phase 4Completed
CompareCT.gov

A Prospective, Randomized Controlled Study to Compare the Effect of Sevoflurane and Propofol for Maintenance of Anesthesia on Postoperative Recovery After Transsphenoidal Resection of Pituitary Adenoma

Peking Union Medical College Hospital·interventional·Posted Apr 21, 2023·Updated Jun 8, 2025

In Brief

A Phase 4 clinical trial evaluating sevoflurane and propofol for Pituitary Adenoma. Completed, enrolled 252 participants across 1 site.

Detailed Summary

Currently, total intravenous anesthesia (TIVA) and inhaled anesthesia are both commonly used for transsphenoidal pituitary adenoma resection. However, optimal choice for anesthesia maintenance in transsphenoidal surgery remains unclear. Previous studies focusing on this question provided fragmentary assessment and controversial results. The goal of this clinical trial is to investigate whether propofol and sevoflurane have different effect on post-anesthetic recovery after transsphenoidal resection of pituitary adenoma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPituitary Adenoma
CountriesChina
Collaborators--

Timeline

Phase 4CompletedFinished
202420252026
First PostedApr 21, 2023
Enrollment StartMay 3, 2023
Primary CompletionApr 29, 2024
Study CompletionAug 14, 2024
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 3.2 years ago

Interventions

sevofluranedrug

Anesthesia is maintained with inhalation of sevoflurane. The concentration of sevoflurane was adjusted to maintain anesthetic depth, aiming for a bispectral index of 40-60.

propofoldrug

Anesthesia is maintained with an effect-site target-controlled infusion of propofol (2-6ug/ml) based on the Marsh mode. The concentration of propofol was adjusted to maintain anesthetic depth, aiming for a bispectral index of 40-60.